Impact Factor
2.95
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
1.47
637 total citations
h5-index
21
h5 depth signal
Cited share
60.4%
279 of 462
Total citations
637
Citation footprint
Metric signal
1.24
External metric anchor
Self-citation
8.6%
55 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
998
Turkey
258
Canada
165
Spain
103
France
94
Citing Fields of Research
Oncology
999
Hematology
597
Pharmacology & Toxicology
353
Patient Care
339
Cancer Drugs
337
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
3,577
Articles tracked across the journal lifetime
Indexed publication set
462
279 cited publications
Last 12 months
270
22.5 publications/month
Open access share
10.4%
28 OA publications in the last year
Leading citing country
United States
998 citing publications
Leading citing field
Oncology
999 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v11n1, Mar. 2005-
v11n1, Mar. 2005-
Research Focus & Classification
Indexed Subjects
Oncology
Hematology
Breast Cancer
Patient Care
Pharmacology & Toxicology
Cancer Drugs
Issuing & Sponsoring Bodies
Contributor
International Society of Oncology Pharmacy Practitioners
Contributor
International Symposium on Oncology Pharmacy Practice
Broad Categories
Neoplasms
Pharmacy
Hematology
Patient Care
Lymphomas
Immunology
Cancer Drugs
Pharmacology & Toxicology
Allergies
MeSH Descriptors
Medical Oncology
Neoplasms
Pharmacy
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1177/10781552261499304
Open DOI
Development of a machine learning-based risk warning model for potentially inappropriate medication use among older patients in a hematology service
Introduction: Older hematology patients often have multiple comorbidities and receive complex medication therapies; this can increase the risk of potentially inappropriate medication (PIM) use. A machine learning model could potentially ...
02
03
DOI 10.1177/10781552261498404
Open DOI
Development, implementation, and evaluation of a mentorship program within hematology/oncology pharmacy association (HOPA) - a professional oncology pharmacy organization
Background: Formal mentorship programs are important for the pharmacy profession. In 2019, the Hematology/Oncology Pharmacy Association (HOPA) launched their Mentorship Program aimed at pairing early-career pharmacists with senior HOPA m...
04
DOI 10.1177/10781552261498054
Open DOI
Medication safety in pediatric oncology survivorship: Polypharmacy, high-risk medications, drug interactions, adherence, and caregiver education
Objective: Medication safety is an underdeveloped dimension of pediatric oncology survivorship despite persistent medication exposure after cancer therapy. This review synthesizes evidence on chronic medication burden and polypharmacy, h...
05
06
DOI 10.1177/10781552261489765
Open DOI
Model informed precision dosing for most accurate busulfan therapeutic drug monitoring
07
DOI 10.1177/10781552261497955
Open DOI
Impact of comedication on survival and toxicity in patients treated with systemic therapy for unresectable hepatocellular carcinoma
Introduction: This study aims to evaluate the association between concomitant medication, survival and toxicity in patients with unresectable hepatocellular carcinoma (uHCC) treated with systemic therapy. Methods: All uHCC patients treat...
08
09
DOI 10.1177/10781552261498242
Open DOI
Drug-related problems and pharmacist interventions within a pharmaceutical care programme in allogeneic haematopoietic stem cell transplantation
Background: Patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT) are exposed to highly complex pharmacotherapy, substantially increasing the risk of drug-related problems (DRPs). Objective: To describe the ...
10
DOI 10.1177/10781552261497394
Open DOI
Wastage of injectable anticancer drugs in a public hospital chemotherapy compounding unit: A prospective descriptive study
Introduction: Evidence on cancer drug wastage comes largely from high-income countries and generally excludes the pediatric setting. This study quantified consumption, leftover reuse and wastage in a chemotherapy compounding unit of the ...
Bibliographical & Catalog Notes
Title from cover.
Vols. for June 1995- accompanied by Symposium issue: 4th- International Symposium on Oncology Pharmacy Practice, 3-6 May 1995- .
Also issued online.